Summary:
- The article explores the chemical and pharmacological distinctions between naturally derived phytocannabinoids and synthetic cannabinoids (such as Delta-8 or HHC produced via isomerization).
- It highlights the importance of precise terminology in scientific and regulatory discourse, emphasizing the difference between structural analogs synthesized in a lab and cannabinoids chemically converted from CBD.
- The text addresses the public health implications of unregulated "synthetic" cannabis products and the lack of standardized testing protocols in the current market.